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Atrial fibrillation is the most common sustained cardiac arrhythmia which is often trou-
blesome to manage. Currently, rhythm and rate control medications are the mainstays of
therapy. In 2 amiodarone-refractory highly symptomatic patients, an innovative approach
using ranolazine, which selectively acts on Naþ channels and delays atrial depolarization,
was tried successfully.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction
Atrial fibrillation (AF) is the most common sustained cardiac
arrhythmia characterized by abnormal automatic firing and
the presence of multiple interacting re-entry circuits looping
around the atria, with consequent deterioration of mechani-
cal function. Episodes of atrial fibrillation are often initiated by
rapid bursts of ectopic beats arising from muscle sleeves tis-
sue in the pulmonary veins or from diseased atrial tissue.1
Currently, rhythm and rate control medications are the
mainstays of therapy, with oral anticoagulation (OAC) therapy
for the prevention of stroke. For rhythm control, amiodarone
is the most potent drug available. In amiodarone-refractory
highly symptomatic patients, innovative approaches are
needed. In this context we tried ranolazine, actually by
serendipity in the first patient. Ranolazine is an anti-anginal
agent, which inhibits normal and abnormal late Naþnstitute, Holy Family Hos
ail.com (Y. Lokhandwala)
2013, Cardiological SocietChannel current in the ventricle and peak Naþ channel cur-
rent in the atrium thus delaying atrial depolarization and
reducing the rate of myocardial contraction.2,32. Case report
2.1. Case 1
A 60-year-old mildly hypertensive physician had been diag-
nosed with hypertrophic non-obstructive apical cardiomyop-
athy in 2004. He developed the first episode of AF in April 2011,
which lasted for 6 h. He continued to have paroxysmal AF at a
frequency of 3 episodes a month, with each paroxysm lasting
6e7 h. Apart from rapid palpitations (ventricular rate @ 130/
min), he used to experience uneasiness, exhaustion, occa-
sional dizziness and exertional left arm pain. Drugs likepital, St. Andrews Road, Bandra, Mumbai 400050, India.
.
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AF. He would take additional propranolol during the episodes.
A coronary angiogram was performed and was found to be
normal. With a suspicion of microvascular angina, ranolazine
was advised. He started taking ranolazine 500 mg twice a day
from July 2012. Amazingly, since then he has had no episodes
of paroxysmal AF in the last 12 months.
2.2. Case 2
A 50-year-old hypertensive, obese and diabetic lady presented
with a history of dyspnea on exertion and occasional chest
pain in September 2012. Her routine biochemistry, hematol-
ogy, ECG and Echocardiogram, in August 2012 had been
normal. She had been on glimepiride and metformin for the
last 2 years, with good sugar control. In addition, she was
taking ramipril and atorvastatin. She started experiencing
dyspnea on routine activities like speaking andwalking so she
underwent a re-evaluation in November 2012. The echocar-
diogram now revealed moderate pulmonary hypertension
(systolic pulmonary artery pressure 52 mmHg). A CT pulmo-
nary angiogram was done to rule out pulmonary embolism; it
was normal. Torsemide was added. The chest X-ray showed
no pleural effusion.
Two weeks later she complained of giddiness followed by
altered sensorium for 3e5 min. She developed left-sided
hemiparesis; the upper limb recovered within a few minutes
but left lower limb paresis persisted. The ECG showed AF with
ventricular rate of 120/min. The echocardiogram did not show
a thrombus. TheMRI of the brain was normal. She was treated
with Low Molecular Weight Heparin and dabigatran was
instituted. The left lower limb weakness resolved after 6 h. A
sleep study revealed obstructive sleep apnea.
She was given a loading dose of amiodarone for 2 weeks
followed by a maintenance dose of 400 mg/day. Verapamil
was concurrently administered. After 6 weeks electrical car-
dioversion was attempted. Despite repeated synchronized
shocks, even using 2 defibrillators simultaneously with 200 J
biphasic shocks each, sinus rhythm could not be restored,
even transiently. She was started on ranolazine 500 mg twice
daily. Sinus rhythm spontaneously returned within a week of
starting this treatment and she has had no recurrence of AF
since then. At 6 months follow up, she was asymptomatic and
the echocardiogram was normal.3. Discussion
AFaccounts for approximately one third ofhospitalizations for
cardiac rhythm disturbances.4 Data from one of the largest
epidemiological studies confirm that AF has a large population
prevalence and incidence.5 It is estimated that life-time risks
for development ofAF are 1 in 4 formenandwomen40years of
age and older.6 During the past 20 years, hospital admissions
forAFhave increasedby66%7due to theagingof thepopulation
and a rising prevalence of chronic heart disease. The incidence
of AF in India is significantly high in younger age group (31e50
years) as compared to Western Europe and USA.8
The management of patients with AF involves three ob-
jectives: (1) Rate Control, (2) Prevention of Thromboembolism,and (3) Rhythm control. For a majority of patients with AF,
there is no long-term cure. Beta-blockers or verapamil are the
commonest drugs for rate control. Class Ic drugs such as
propafenone or flecainide are reasonably effective for rhythm
control in structurally normal hearts. Sotalol is an option for
rhythm control. Amiodarone is the most potent for rhythm
control, but its use is restricted to patients in whom other
measures fail, due to its long-term side effects. Negative ino-
tropy and ventricular proarrhythmia are limitations to the
current drug therapies used in AF.9 Thus, the development of
agents that preferentially modulate the function of atrial ion
channel currents is an attractive therapeutic strategy. One
such approach is the use of agents that selectively act on atrial
sodium channels.
In atria, unlike in ventricles, ranolazine produces a signif-
icant reduction in excitability, leading to the development of a
prominent rate-dependent post repolarization refractoriness
(PRR).2 This effect could potentially block re-entrant path-
ways. However, it is its effect on triggered activity, which
appear most powerful. Burashnikov et al2 demonstrated sig-
nificant differences in the inactivation characteristics of atrial
versus ventricular sodium channels. This study identified
ranolazine to be capable of exploiting the differences in so-
dium channel inactivation between atrial and ventricular
cells. Ranolazine showed striking atrial selectively, leading to
depression of excitability and suppression of AF. Ranolazine
inhibits normal and abnormal late Naþ channel current in the
ventricle and peak Naþ channel current in the atrium.2,10,11 By
this inhibition, it affects intracellular calcium handling, pro-
ducing an energy sparing effect.10 Ranolazine has also been
shown to be a potent inhibitor of after-depolarization pro-
duced by a number of mechanisms.11e13 It slightly prolongs
the action potential duration by inhibiting the slow sodium
current and the slow component of the delayed rectifying
potassium current.3,12
Ranolazine suppresses proarrhythmogenic mechanisms
in vitro14 and has a low proarrhythmic potential in vivo.3,15
The MERLINeTIMI 36 trial16 revealed that ranolazine signifi-
cantly reduces the incidence of supraventricular arrhythmias
and new episodes of AF in patients with non-ST segment
elevation acute coronary syndrome. Miles et al17 concluded
that ranolazine could prove useful in the treatment of AF in
general and AF after CABG in particular. A proof-of-concept
study by Fragakis et al18 reported the synergistic effect of
amiodarone and ranolazine for conversion of AF. Richard L
et al19 observed that concurrent administration of ranolazine
and dronedarone at doses in the low therapeutic range exerts
dual protection against ischemia-induced vulnerability to AF
and ventricular arrhythmias.
The complex nature of ranolazine’s antiarrhythmic effects
is largely a result of the drug’s effect onmultiple ion channels:
it inhibits the late rectifying potassium channel, and the late
L-type calcium channel. Whereas inhibition of the potassium
channel increases the action potential duration, inhibition of
the other 2 channels shortens the action potential.20 This
physiologic effect seems to explain the modest increase in
QTc interval that was observed in some clinical trials. In the
CARISA trial, the mean increase in QTC was 6.1 ms in the 750-
mg ranolazine group and 9.2 ms in the 1000-mg group. Similar
increases over the baseline QTc interval were seen in the
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concern about drug-induced torsades de pointes. However,
none of the 4 major clinical trials22e25 produced evidence of
that phenomenon. The absence of this expected effect is
partially explained by the absence of early afterdepolarization
and increased dispersion of ventricular repolarization.
The most common side effects of ranolazine are dizziness,
nausea, constipation, and headache. Less than 2% of patients
experience these side effects.23e25 In most cases, the symp-
toms aremild, and occurwithin the first fewweeks of therapy.
Although some patients must discontinue taking the drug,
most can tolerate reduced dosages.
Maintaining sinus rhythm in patients with AF can be
particularly challenging. Despite anti-arrhythmic therapy, AF
persisted in the two patients presented in our report. Rano-
lazine, however, was effective in suppressing AF in both pa-
tients despite associated medical conditions such as
hypertension, diabetes mellitus, obesity and obstructive sleep
apnea.4. Conclusion
Though the use of ranolazine as an anti-arrhythmic agent has
not been established, in reviewed literature and in our pa-
tients, it has proven to be effective in suppressing AF in re-
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